Daiichi Sankyo
Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We provide innovative products and services in more than 20 countries around the world. With more than 100 years of scientific expertise, our company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients.
Through the outstanding knowledge and commitment of our 15,000 employees worldwide, we create innovative new and generic medicines, and new methods of drug discovery and delivery. We share a passion for innovation, as well as compassion for the patients around the world who are in need of our medicines.
To contribute to the enrichment of quality of life around the world through the creation of innovative pharmaceuticals, and through the provision of pharmaceuticals addressing diverse medical needs.
Our vision is to become a Global Pharma Innovator – a company that continuously develops innovative medicines – by 2015. We’re working to achieve this through social, economic and humanistic means:
Business Strategy
As a research-based pharmaceutical company, we focus on providing solutions to address unmet medical needs of patients around the world. We operate in a high-risk business sector – and in an age in which many countries are limiting their healthcare spending. To meet these challenges, we continue to invest in our Japanese, U.S. and European core markets, as well as emerging markets in developing and recently industrialized countries. Our diverse portfolio includes innovative and generic pharmaceuticals, vaccines, and over-the-counter medicines.
Partnerships, Licensing and Acquisitions
To expand our business and achieve long-term growth, we’re partnering on high-potential products that complement our in-house portfolio. We focus our acquisition activities on new products and product candidates, and companies that drive our portfolio in key therapeutic categories. We have a special interest in biotech companies, as well as products and licenses related to the fields of oncology and cardiovascular and metabolic diseases.